Chemomab Therapeutics (CMMB)
(Delayed Data from NSDQ)
$0.62 USD
-0.02 (-3.11%)
Updated Apr 29, 2024 09:30 AM ET
3-Hold of 5 3
D Value B Growth B Momentum C VGM
Price, Consensus and EPS Surprise
CMMB 0.62 -0.02(-3.11%)
Will CMMB be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for CMMB based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CMMB
Here's Why Chemomab Therapeutics Ltd. Sponsored ADR (CMMB) Is a Great 'Buy the Bottom' Stock Now
Chemomab (CMMB) Up on Fast Track Designation to CM-101 for PSC
CMMB: What are Zacks experts saying now?
Zacks Private Portfolio Services
Intercept's (ICPT) NDA for NASH Treatment Accepted By FDA
Intercept (ICPT) Gains 12.4% in the Past Six Months: Here's Why
The Zacks Analyst Blog Highlights Geron, Chemomab Therapeutics, Phathom Pharmaceuticals, Vera Therapeutics and Novavax
Other News for CMMB
Chemomab Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update
Chemomab Reports New Peer-Reviewed Publication Reinforcing the Clinical Association of Its CCL24 Target with Disease Severity and Mortality in Patients with Systemic Sclerosis
Chemomab Therapeutics reports publication on its CCL24 target, SSc
Chemomab Therapeutics to hold a conference call
Chemomab Therapeutics to hold a conference call